LLY compared with PRLD: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

PRLDPrelude Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

PRLD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.9%▲+10.14%×0.56

= impliedLLY realized, solidPRLD realized, hatchedOne scale, both sides: full bar = 18%× = |realized| ÷ impliedSource: market data

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

PRLDPrelude Therapeutics Inc

3.61▲+1.55%· post 3.61

ClosedNov 6 '26

Mkt cap$287.3MRevenue$6MQ2 FY26Revenue—

Compare

ClosedNov 6 '26

LLYELI Lilly & Co

PRLDPrelude Therapeutics Inc

1,360.90▼−0.28%post 1,358.90

Price

3.61▲+1.55%post 3.61

$1.2T

Mkt cap

$287.3M

Q3 FY26$24.4B

Revenue

$6MQ2 FY26

FY25$65.2B

Revenue

—

LLY1,360.90▼−0.28%vsPRLD3.61▲+1.55%ClosedNov 6 '26